logo
Twitter
Discord
Email
logo
AbCellera Biologics Inc.

AbCellera Biologics Inc.

NASDAQ•ABCL
CEO: Dr. Carl L.G. Hansen Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-12-11
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Contact Information
2215 Yukon Street, Vancouver, BC, V5Y 0A1, Canada
604-559-9005
www.abcellera.com
Market Cap
$1.23B
P/E (TTM)
-7.2
38.2
Dividend Yield
--
52W High
$6.52
52W Low
$1.89
52W Range
48%
Rank37Top 34.1%
4.4
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 4.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$8.96M+37.62%
4-Quarter Trend

EPS

-$0.19+11.77%
4-Quarter Trend

FCF

-$61.52M+29.30%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth 27% Total revenue reached 30.3M USD for nine months ended September 30, 2025, marking a 27% increase from prior period.
Operating Loss Reduced Loss from operations narrowed by 53.5M USD to (188.5M USD) for the nine months ended September 30, 2025.
Pipeline Molecules Advance Molecules in the clinic increased to 18 as of September 30, 2025, representing 29% growth over the prior period.
Partner Programs Expanding Partner-initiated program starts with downstreams grew 8% to 103 cumulatively, indicating strong partnership pipeline activity.

Risk Factors

Continued Operating Losses Expect continued expenditures and operating losses for the foreseeable future; profitability timing remains uncertain, impacting capital needs.
Partner Development Reliance Business success heavily relies on partners successfully developing and commercializing discovered antibodies; this is outside of management control.
Cash Burn and Liquidity Total cash and marketable securities decreased by 129.9M USD since year-end 2024, driven by ongoing research and development cash use.
Intellectual Property Enforcement Failure to maintain broad IP protection or successfully defend against challenges could allow competitors to copy core technology.

Outlook

Final Platform Investments On track to complete final large platform investments, including clinical manufacturing facility, during the 2025 fiscal year.
Internal Pipeline Advancement Advanced ABCL688 into IND/CTA-enabling studies; expect IND/CTA submission for this autoimmunity program in 2026.
Sufficient Liquidity Runway Available liquidity expected to meet working capital and CapEx needs for at least the next 36 months based on current plan.

Peer Comparison

Revenue (TTM)

Arcus Biosciences, Inc.RCUS
$240.00M
-8.7%
Viridian Therapeutics, Inc.VRDN
$70.79M
+23340.1%
Ocular Therapeutix, Inc.OCUL
$55.72M
-9.2%

Gross Margin (Latest Quarter)

Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp
Janux Therapeutics, Inc.JANX
95.0%
-5.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CELC$4.95B-29.4-179.0%67.3%
VERA$3.26B-11.8-50.9%14.9%
EWTX$2.90B-18.4-30.9%0.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
21.0%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:-$0.16
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $8.96M+37.6%
    |
    EPS: $-0.19+11.8%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $17.08M+133.3%
    |
    EPS: $-0.12-7.7%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $4.24M-57.5%
    |
    EPS: $-0.15+7.1%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $28.83M-24.2%
    |
    EPS: $-0.55-7.8%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 4, 2024|
    Revenue: $6.51M-1.4%
    |
    EPS: $-0.17+72.1%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $7.32M-27.2%
    |
    EPS: $-0.13+18.2%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $9.95M-18.4%
    |
    EPS: $-0.14+0.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 20, 2024|
    Revenue: $38.03M-92.2%
    |
    EPS: $-0.51-191.1%
    Miss